IRIS Accounts Production v26.1.10.61 12520688 Board of Directors 1.4.25 31.3.26 31.3.26 false true false false true false iso4217:GBPiso4217:USDiso4217:EURxbrli:sharesxbrli:pureutr:tonnesutr:kWh125206882025-03-31125206882026-03-31125206882025-04-012026-03-31125206882024-03-31125206882024-04-012025-03-31125206882025-03-3112520688ns15:EnglandWales2025-04-012026-03-3112520688ns14:PoundSterling2025-04-012026-03-3112520688ns10:Director12025-04-012026-03-3112520688ns10:PrivateLimitedCompanyLtd2025-04-012026-03-3112520688ns10:SmallEntities2025-04-012026-03-3112520688ns10:AuditExempt-NoAccountantsReport2025-04-012026-03-3112520688ns10:SmallCompaniesRegimeForDirectorsReport2025-04-012026-03-3112520688ns10:SmallCompaniesRegimeForAccounts2025-04-012026-03-3112520688ns10:FullAccounts2025-04-012026-03-3112520688ns5:CurrentFinancialInstruments2026-03-3112520688ns5:CurrentFinancialInstruments2025-03-3112520688ns5:ShareCapital2026-03-3112520688ns5:ShareCapital2025-03-3112520688ns5:RetainedEarningsAccumulatedLosses2026-03-3112520688ns5:RetainedEarningsAccumulatedLosses2025-03-3112520688ns10:RegisteredOffice2025-04-012026-03-3112520688ns5:PlantMachinery2025-04-012026-03-3112520688ns5:ComputerEquipment2025-03-3112520688ns5:ComputerEquipment2025-04-012026-03-3112520688ns5:ComputerEquipment2026-03-3112520688ns5:ComputerEquipment2025-03-3112520688ns5:WithinOneYearns5:CurrentFinancialInstruments2026-03-3112520688ns5:WithinOneYearns5:CurrentFinancialInstruments2025-03-31
REGISTERED NUMBER: 12520688 (England and Wales)
























GDP PHARMA CONSULTING LTD

UNAUDITED FINANCIAL STATEMENTS

FOR THE YEAR ENDED 31 MARCH 2026






GDP PHARMA CONSULTING LTD (REGISTERED NUMBER: 12520688)

CONTENTS OF THE FINANCIAL STATEMENTS
FOR THE YEAR ENDED 31 MARCH 2026










Page

Balance Sheet 1

Notes to the Financial Statements 3


GDP PHARMA CONSULTING LTD (REGISTERED NUMBER: 12520688)

BALANCE SHEET
31 MARCH 2026

2026 2025
Notes £    £    £    £   
FIXED ASSETS
Tangible assets 4 3,862 4,828

CURRENT ASSETS
Debtors 5 78,803 61,664
Cash at bank 97,722 162,493
176,525 224,157
CREDITORS
Amounts falling due within one year 6 53,534 120,515
NET CURRENT ASSETS 122,991 103,642
TOTAL ASSETS LESS CURRENT LIABILITIES 126,853 108,470

PROVISIONS FOR LIABILITIES 965 1,207
NET ASSETS 125,888 107,263

CAPITAL AND RESERVES
Called up share capital 100 100
Retained earnings 125,788 107,163
125,888 107,263

The company is entitled to exemption from audit under Section 477 of the Companies Act 2006 for the year ended 31 March 2026.

The members have not required the company to obtain an audit of its financial statements for the year ended 31 March 2026 in accordance with Section 476 of the Companies Act 2006.

The directors acknowledge their responsibilities for:
(a)ensuring that the company keeps accounting records which comply with Sections 386 and 387 of the Companies Act 2006 and
(b)preparing financial statements which give a true and fair view of the state of affairs of the company as at the end of each financial year and of its profit or loss for each financial year in accordance with the requirements of Sections 394 and 395 and which otherwise comply with the requirements of the Companies Act 2006 relating to financial statements, so far as applicable to the company.

GDP PHARMA CONSULTING LTD (REGISTERED NUMBER: 12520688)

BALANCE SHEET - continued
31 MARCH 2026


The financial statements have been prepared and delivered in accordance with the provisions applicable to companies subject to the small companies regime.

In accordance with Section 444 of the Companies Act 2006, the Profit and Loss Account has not been delivered.

The financial statements were approved by the Board of Directors and authorised for issue on 29 July 2026 and were signed on its behalf by:





Mrs C Glenister - Director


GDP PHARMA CONSULTING LTD (REGISTERED NUMBER: 12520688)

NOTES TO THE FINANCIAL STATEMENTS
FOR THE YEAR ENDED 31 MARCH 2026


1. STATUTORY INFORMATION

GDP Pharma Consulting Ltd is a private company, limited by shares , registered in England and Wales. The company's registered number and registered office address are as below:

Registered number: 12520688

Registered office: 6-7 Castle Gate
Castle Street
Hertford
Hertfordshire
SG14 1HD

2. ACCOUNTING POLICIES

Basis of preparing the financial statements
These financial statements have been prepared in accordance with Financial Reporting Standard 102 "The Financial Reporting Standard applicable in the UK and Republic of Ireland" including the provisions of Section 1A "Small Entities" and the Companies Act 2006. The financial statements have been prepared under the historical cost convention.

Turnover
Turnover is measured at the fair value of the consideration received or receivable, excluding discounts, rebates, value added tax and other sales taxes.

Tangible fixed assets
Depreciation is provided at the following annual rates in order to write off each asset over its estimated useful life.
Plant and machinery etc - 20% on reducing balance

Taxation
Taxation for the year comprises current and deferred tax. Tax is recognised in the Profit and Loss Account, except to the extent that it relates to items recognised in other comprehensive income or directly in equity.

Current or deferred taxation assets and liabilities are not discounted.

Current tax is recognised at the amount of tax payable using the tax rates and laws that have been enacted or substantively enacted by the balance sheet date.

Deferred tax
Deferred tax is recognised in respect of all timing differences that have originated but not reversed at the balance sheet date.

Timing differences arise from the inclusion of income and expenses in tax assessments in periods different from those in which they are recognised in financial statements. Deferred tax is measured using tax rates and laws that have been enacted or substantively enacted by the year end and that are expected to apply to the reversal of the timing difference.

Unrelieved tax losses and other deferred tax assets are recognised only to the extent that it is probable that they will be recovered against the reversal of deferred tax liabilities or other future taxable profits.

Pension costs and other post-retirement benefits
The company operates a defined contribution pension scheme. Contributions payable to the company's pension scheme are charged to profit or loss in the period to which they relate.

GDP PHARMA CONSULTING LTD (REGISTERED NUMBER: 12520688)

NOTES TO THE FINANCIAL STATEMENTS - continued
FOR THE YEAR ENDED 31 MARCH 2026


2. ACCOUNTING POLICIES - continued

Debtors
Short term debtors are measured at transaction price (which is usually the invoice price), less any impairment losses for bad and doubtful debts. Loans and other financial assets are initially recognised at transaction price including any transaction costs and subsequently measured at amortised cost determined using the effective interest method, less any impairment losses for bad and doubtful debts.

Creditors
Short term creditors are measured at transaction price (which is usually the invoice price). Loans and other financial liabilities are initially recognised at transaction price net of any transaction costs and subsequently measured at amortised cost determined using the effective interest method.

3. EMPLOYEES AND DIRECTORS

The average number of employees during the year was 3 (2025 - 2 ) .

4. TANGIBLE FIXED ASSETS
Computer
equipment
£   
COST
At 1 April 2025
and 31 March 2026 11,498
DEPRECIATION
At 1 April 2025 6,670
Charge for year 966
At 31 March 2026 7,636
NET BOOK VALUE
At 31 March 2026 3,862
At 31 March 2025 4,828

5. DEBTORS: AMOUNTS FALLING DUE WITHIN ONE YEAR
2026 2025
£    £   
Trade debtors 49,798 51,659
Other debtors 29,005 10,005
78,803 61,664

6. CREDITORS: AMOUNTS FALLING DUE WITHIN ONE YEAR
2026 2025
£    £   
Taxation and social security 51,072 57,175
Other creditors 2,462 63,340
53,534 120,515

GDP PHARMA CONSULTING LTD (REGISTERED NUMBER: 12520688)

NOTES TO THE FINANCIAL STATEMENTS - continued
FOR THE YEAR ENDED 31 MARCH 2026


7. RELATED PARTY DISCLOSURES

During the year, the directors loaned the company money with no set repayment date. At the year end the amount due from the company to the directors was £2,461 (2025:£63,340).

8. ULTIMATE CONTROLLING PARTY

The company is controlled equally by the directors C Glenister and P Coombs.